Sanofi to buy US biopharma group Blueprint Medicines for $9.1 Billion equity value

Jun 02, 2025 04:55 PM IST

Sanofi will purchase Blueprint Medicines for $9.1 billion to bolster its rare disease portfolio.

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio.

Sanofi will pay $129 per share in cash, the companies said in a statement Monday. (AFP)

Sanofi will pay $129 per share in cash, the companies said in a statement Monday. That represents a 27% premium to Blueprint’s closing price on Friday.

Blueprint shareholders will also receive one non-tradeable contingent value right, which will pay the holder $2 and $4 per right for the achievement, respectively, of future development and regulatory milestones for BLU-808 — a potential treatment for patients with mast cell disorders, including chronic urticaria.

Including the potential CVR payments, the deal amounts to about $9.5 billion on a fully diluted basis.

Sanofi expects to complete the acquisition in the third quarter and said the deal won’t have a significant impact on its financial guidance for 2025.

Stay updated with US News covering politics, crime, weather, local events, and sports highlights. Get the latest on Donald Trump and American politics. Stay updated with US News covering politics, crime, weather, local events, and sports highlights. Get the latest on Donald Trump and American politics. News / World News / US News / Sanofi to buy US biopharma group Blueprint Medicines for $9.1 Billion equity value